Objective: Disulfiram (DSF), an inhibitor of acetaldehyde dehydrogenase that is used for the treatment of alcoholism, was shown to reactivate latent HIV-1 expression in a primary cell model of virus latency and is currently being assessed in a clinical trial for its potential to deplete the latent HIV-1 reservoir in patients on combination antiretroviral therapy. The mechanism by which DSF reactivates latent HIV-1 expression, however, is not known and was the focus of this study.
Design/methods: The impact of DSF treatment on HIV-1 latency was assessed in the ACH2, J89GFP and U1 cell line models of HIV-1 latency and in resting CD4+ T cells isolated from HIV-negative donors.
Results: DSF reactivated latent HIV-1 expression in the U1 cell line, but not in the J89GFP or ACH2 cell lines. Interestingly, we found that DSF significantly reduced phosphatase and tensin homolog (PTEN) protein levels in U1 cells and in resting CD4+ T cells from HIV-negative donors. Decreased PTEN resulted in increased phosphorylation of protein kinase B (Akt) and activation of the Akt signaling pathway. Consistent with these finding, pharmacological inhibitors of Akt and nuclear factor-kappaB (NF-κB) block the latent HIV-1-reactivating activity of DSF. Furthermore, we show that HIV-1 expression in the U1 cell line could be activated by a small molecule inhibitor of PTEN or by siRNA knockdown of PTEN expression. Neither the J89GFP nor ACH2 cells express PTEN, explaining the lack of DSF effect on HIV-1 expression in both these cell lines.
Conclusion: DSF reactivates latent HIV-1 expression via the Akt signaling pathway through depletion of PTEN.
Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Correspondence to Nicolas Sluis-Cremer, S817 Scaife Hall, 3550 Terrace Street, Pittsburgh, PA 15261, USA. Tel: +1 412 648 8457; fax: +1 412 648 8521; e-mail: email@example.com
Received 5 April, 2012
Revised 29 May, 2012
Accepted 15 June, 2012
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.AIDSonline.com).
Although combination antiretroviral therapy (cART) can efficiently reduce plasma HIV-1 levels in infected individuals to below the limit of detection (<50 copies/ml), it has no impact on the latent reservoir that resides in resting CD4+ T cells . In this reservoir, the integrated provirus remains transcriptionally silent as long as the host cell is in a resting state. However, upon cellular activation, HIV-1 RNA is transcribed and virus is produced, providing a source for recrudescent infection upon cessation of cART. The latent reservoir in resting CD4+ T cells is extremely stable with an estimated half-life of approximately 44 months, which effectively means that more than 60 years of therapy would be required to eliminate it [2,3]. A prevailing hypothesis in the field is that intervention strategies that reactivate latent HIV-1 infection will purge this reservoir by inducing transcription of the latent provirus, thereby causing cells to undergo apoptosis. Ongoing cART will prevent infection of new cells with the net result being reduction in the latent reservoir. Antiviral immune responses may also aid in the clearance of infected cells, and prevent the spread of infection to other cells. With regard to inducing HIV-1 transcription, Xing et al. demonstrated in a primary CD4+ T-cell model that disulfiram (DSF), a United States Food and Drug Administration approved drug used to treat chronic alcoholism, reactivates latent HIV-1 without global T-cell activation. On the basis of this finding, an ongoing clinical trial is determining whether a 2-week course of DSF will reduce the HIV-1 latent reservoir in patients on cART (ClinicalTrials.gov identifier: NCT01286259). Preliminary results from this trial revealed that DSF administration resulted in a small transient increase in viral load in some trial participants that was not statistically significant. Furthermore, a modest 14% decline in the size of the latent reservoir was noted . Despite its evaluation in clinical trials, the mechanism(s) by which DSF reactivates latent HIV-1 expression has not been elucidated. As such, the primary objective of the current study was to address this important knowledge gap.
DSF was obtained from Sigma-Aldrich (St Louis, Missouri, USA). The phosphatase and tensin homolog (PTEN), phospho-Akt and Akt antibodies were obtained from Cell Signaling Technology (Boston, Massachusetts, USA). The β-actin antibody was obtained from Abcam (Cambridge, Massachusetts, USA). The Akt inhibitor VIII, cyclosporine A, SP600125 and Go6983 were purchased from Sigma Aldrich. Potassium bisperoxo (1,10-phenanthroline) oxovanadate [bpV(phen)] and the NF-κB activation inhibitor were acquired from EMD Biosciences (San Diego, California, USA). DNA primers were synthesized by Integrated DNA Technologies (San Diego, California, USA). Cellular proteins were separated using 4–12% SDS-PAGEs from Invitrogen (Grand Island, New York, USA). Immunodetection was performed using the Millipore SNAP i.d. (Billerica, Massachusetts, USA).
Cells and cell culture
ACH2 and U1 cells were obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health (T. Folks, contributor) [6–8]. J89GFP cells were a kind gift from D. Levy . All three cell lines were maintained in RMPI 1640 medium supplemented with 10% fetal bovine serum, 0.3-mg/ml L-glutamine, 100-U/ml penicillin and 100-μg/ml streptomycin at 37°C in humidified air with 5% CO2.
Isolation of resting CD4+ T cells from HIV-negative donors
One hundred milliliter of blood was obtained from healthy HIV-negative volunteers. Donation was approved by the University of Pittsburgh Institutional Review Board. Written informed consent was provided for all volunteer donors. Resting CD4+ T cells were isolated from peripheral blood mononuclear cells by magnetic bead selection (Miltenyi Biotech, Cambridge, Massachusetts, USA) as described previously .
Small interfering RNA knockdown
Small interfering RNAs (siRNAs) targeting PTEN, as well as a control scrambled sequence control siRNA, were purchased from Qiagen (SA Biosciences, Qiagen Inc., Valencia, California, USA). U1 cells were transfected with 80-nmol/l siRNA using the Neon Transfection System from Invitrogen, according to the manufacturer's protocol. The efficiency of gene knockdown was assessed by determining mRNA levels and by western blot analyses of protein expression.
Quantitative analysis of gene transcripts
RNA was extracted from cells using the RNeasy Plus RNA extraction kit (Qiagen Inc.) according to the manufacturer's protocol. RNA was quantified using a Nanodrop 2000, and 400 ng of total RNA was used in each reverse transcription (RT) PCR reaction. Amplification was performed using the QuantiTect SYBR Green RT-PCR kit (Qiagen Inc.) and the DNA Engine Opticon system (Bio-Rad Hercules, California, USA). Initiated and elongated HIV-1 transcripts were assessed as described previously .
Results and discussion
Disulfiram reactivates HIV-1 expression in the U1 but not ACH2 or J89GFP cell line models of latency
We first assessed the ability of DSF to induce HIV-1 expression in three different cell line models of HIV-1 latency, namely ACH2, J89GFP and U1. The ACH2 and J89GFP cell lines are chronically HIV-1-infected T-lymphocytic cells. ACH2 cells are a subclone of A3.01, which is derived from CEM, a human T-cell line originally isolated from a 4-year-old female with acute lymphoblastic lymphoma, whereas the J89GFP cell line was established from the peripheral blood of a 14-year-old male with T-cell leukemia. By contrast, U1 cells are an HIV-1-infected monocytic cell line, subcloned from the U937 cell line, which was isolated from a pleural effusion of a 2-year-old male with diffuse histiocytic lymphoma. Reactivation of latent HIV-1 expression in each of these cell lines was measured by quantitative assessment of early and late viral RNA transcripts (Fig. 1a; Supplementary Table 1, http://links.lww.com/QAD/A230). DSF was found to reactivate latent HIV-1 RNA expression in the U1 cell line, but not in the ACH2 or J89GFP cell lines. To investigate further this finding, we searched for functional differences in the three cell lines that could potentially account for the differential activity of DSF.
The ACH2 and J89GFP cell lines lack the phosphatase and tensin homolog
PTEN is a tumor suppressor gene that is frequently mutated in many different cancers. It negatively regulates intracellular levels of phosphatidylinositol-3,4,5-trisphosphate (PIP3) in cells and functions as a tumor suppressor by negatively regulating the Akt signaling pathway. The Jurkat T-cell line is PTEN-null [12–14]. Similarly, CEM cells have a deletion in exons 2–5 of the PTEN gene  that corresponds to the phosphatase domain and renders the protein unstable . By contrast, PTEN is expressed in the U1 cell line and in resting CD4+ T cells isolated from HIV-negative donors (Fig. 1B).
Disulfiram depletes phosphatase and tensin homolog and activates the Akt signaling pathway
A prior study showed that DSF led to decreased expression of PTEN and activation of Akt in a dose-dependent and time-dependent manner in human breast cancer cells . Therefore, we assessed whether DSF treatment in both U1 cells and in resting CD4+ T cells impacted PTEN expression and/or activation of Akt. We found that DSF treatment depleted PTEN levels and increased Akt phosphorylation in both cell types (Fig. 1c, d). Interestingly, quantitative PCR analyses revealed that DSF did not impact PTEN expression at the RNA level (data not shown). Furthermore, DSF did not trigger Akt activation in either ACH2 or J89GFP cells, which lack PTEN (Fig. 1e).
Disulfiram reactivates latent HIV-1 expression via the Akt signaling pathway
To determine whether PTEN depletion and Akt activation contributed to the latent HIV-1 reaction phenotype of DSF in U1 cells, we assessed its activity in combination with inhibitors that targeted Akt or NF-κB (a downstream target of Akt). The Akt inhibitor VIII reduced the activity of DSF in a dose-dependent manner (Fig. 2a). Similarly, the NF-κB activation inhibitor completely negated DSF activity. By contrast, inhibitors of the nuclear factor of activated T cells, protein kinase C (PKC) and the c-Jun N-terminal kinase did not affect DSF activity. Of note, a control experiment was also performed using the PKC agonist prostratin instead of DSF. Consistent with its mechanism of action, the latent reactivation activity of prostratin was only diminished by a PKC inhibitor. To directly determine the role of PTEN in maintaining the HIV-1 latent phenotype in U1 cells, we assessed the ability of a high-affinity PTEN inhibitor [bpV(phen)]  to stimulate HIV-1 RNA expression. The bpV(phen) was found to be a potent activator of HIV-1 expression in the U1 cell line (Fig. 2b). Furthermore partial knockdown of PTEN expression by siRNA also resulted in reactivation of latent HIV-1 expression in the U1 cell line (Fig. 2c). Taken together, these data demonstrate that DSF reactivates latent HIV-1 via the Akt signaling pathway through depletion of PTEN. They also provide strong evidence that PTEN is a key regulator of HIV-1 latency.
PTEN dephosphorylates PIP3, resulting in the biphosphate product phosphatidylinositol 4,5-bisphosphate. This dephosphorylation is important because it mediates inhibition of the Akt signaling pathway that controls multiple cellular processes including transcription. In this study, we show that DSF also reactivates latent HIV-1 expression via the Akt signaling pathway through depletion of PTEN. This mechanism is unrelated to the activity of DSF as an inhibitor of aldehyde dehydrogenase, which is the basis for its clinical use to prevent alcohol intake. Of note, prior studies have demonstrated that both histone deacetylase inhibitors [11,18] and hexamethylene bisacetamide  reactivate latent HIV-1 through activation of the Akt signaling pathway. In this regard, activated Akt phosphorylates hexamethylene bis-acetamide inducible 1 (HEXIM1), which results in the subsequent release of the active positive transcription elongation factor b (p-TEFb) from its transcriptionally inactive complex with HEXIM1 and the 7SK small nuclear protein. As a result, p-TEFb is recruited to the HIV-1 promoter to stimulate transcription elongation and viral production . Importantly, our findings suggest that PTEN could be targeted to reverse HIV-1 latency. They also suggest that Akt phosphorylation and/or PTEN depletion could serve as a pharmacodynamic marker of DSF activity in vivo. Finally, our research highlights the limitations of studying HIV-1 latency in cell lines. Many of these cell lines were isolated from human cancers and have mutations and/or deletions in genes encoding key enzymes/proteins involved in signal transduction pathways that may play important roles in regulating HIV-1 latency.
Conflicts of interest
There are no conflicts of interest.
1. Trono D, Van Lint C, Rouzioux C, Verdin E, Barré-Sinoussi F, Chun TW, Chomont N. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals
2. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells
. Nat Med
3. Strain MC, Günthard HF, Havlir DV, Ignacio CC, Smith DM, Leigh-Brown AJ, et al. Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence
. Proc Natl Acad Sci U S A
4. Xing S, Bullen CK, Shroff NS, Shan L, Yang HC, Manucci JL, et al. Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation
. J Virol
5. Spivak A, Andrade A, Hoh R, Bacchetti P, Eisele E, Buckheit III R, et al.Safety and feasibility of using disulfiram to enhance HIV transcription among long-term ARV-treated adults: preliminary results from a pilot study [abstract]. In:19th Conference on Retrovirus and Opportunistic Infections
; 5–8 March 2012; Seattle, Washington, USA.
6. Clouse KA, Powell D, Washington I, Poli G, Strebel K, Farrar W, et al. Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone
. J Immunol
7. Folks TM, Clouse KA, Justement J, Rabson A, Duh E, Kehrl JH, Fauci AS. Tumor necrosis factor a induces expression of human immunodeficiency virus in a chronically infected T-cell clone
. Proc Natl Acad Sci USA
8. Folks TM, Justement J, Kinter A, Dinarello CA, Fauci AS. Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line
9. Kutsch O, Benveniste EN, Shaw GM, Levy DN. Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency
. J Virol
10. Saleh S, Solomon A, Wightman F, Xhilaga M, Cameron PU, Lewin SR. CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection: a novel model of HIV-1 latency
11. Huber K, Doyon G, Plaks J, Fyne E, Mellors JW, Sluis-Cremer N. Inhibitors of histone deacetylases: correlation between isoform specificity and reactivation of HIV type 1 (HIV-1) from latently infected cells
. J Biol Chem
12. Sakai A, Thieblemont C, Wellmann A, Jaffe ES, Raffeld M. PTEN gene alterations in lymphoid neoplasms
13. Shan X, Czar MJ, Bunnell SC, Liu P, Liu Y, Schwartzberg PL, Wange RL. Deficiency of PTEN in Jurkat T cells causes constitutive localization of Itk to the plasma membrane and hyperresponsiveness to CD3 stimulation
. Mol Cell Biol
14. Xu Z, Stokoe D, Kane LP, Weiss A. The inducible expression of the tumor suppressor gene PTEN promotes apoptosis and decreases cell size by inhibiting the PI3K/Akt pathway in Jurkat T cells
. Cell Growth Differ
15. Georgescu MM, Kirsch KH, Akagi T, Shishido T, Hanafusa H. The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region
. Proc Natl Acad Sci U S A
16. Zhang H, Chen D, Ringler J, Chen W, Cui QC, Ethier SP, et al. Disulfiram treatment facilitates phosphoinositide 3-kinase inhibition in human breast cancer cells in vitro and in vivo
. Cancer Res
17. Schmid AC, Byrne RD, Vilar R, Woscholski R. Bisperoxovanadium compounds are potent PTEN inhibitors
. FEBS Lett
18. Contreras X, Schweneker M, Chen CS, McCune JM, Deeks SG, Martin J, Peterlin BM. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells
. J Biol Chem
19. Contreras X, Barboric M, Lenasi T, Peterlin BM. HMBA releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K/Akt and activates HIV transcription
. PLoS Pathog